Trial Profile
A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Enalapril; Losartan; Prednisolone
- Indications IgA nephropathy
- Focus Adverse reactions; Therapeutic Use
- 14 Oct 2015 New trial record